


Quinacainol

Chemical Properties

| | |
|-------------------|---|
| CAS No. : | 86073-85-0 |
| Formula: | C ₂₁ H ₃₀ N ₂ O |
| Molecular Weight: | 326.48 |
| Storage: | Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA. |



Biological Description

| | |
|---------------|--|
| Description | Quinacainol (RP 54272) is a new antiarrhythmic compound with class I antiarrhythmic effects in rats. |
| Targets(IC50) | Others,Sodium Channel |
| In vitro | Quinacainol blocked sodium currents in a concentration-dependent manner and with a potency similar to that of quinidine (mean (+/-SEM) EC50 50+/-12 vs 95+/-25 micromol/L for quinidine and quinacainol, respectively). Quinacainol, a quinidine analog, blocks sodium currents in cardiac myocytes with little effect on I (to) or iKsus potassium currents, which suggests that quinacainol may be exerting class 1c anti-arrhythmic actions.[1] |
| In vivo | Evaluation of antiarrhythmic effects using Quinacainol in conscious rats with LAD coronary artery occlusion. Antiarrhythmic actions occurred with 2.0 and 4.0 mg/kg, whereas 8.0 mg/kg was pro-arrhythmic. At doses of 0.5 mg/kg and above, quinacainol increased threshold currents for capture and for ventricular fibrillation. Doses of 2.0 mg/kg and above increased ventricular refractoriness. From 1.0 to 8.0 mg/kg, quinacainol reduced dV/dtmax of phase 0 of epicardial action potentials but only 8.0 mg/kg increased action potential duration. The Q-T interval was also increased with the highest dose. Quinacainol dose-relatedly increased P-R interval whereas QRS did not change. Thus the Class I electrophysiological properties of quinacainol over the dose range tested did not fit accurately into a single subclass of the various subclasses of Class I. However, the Class Ic actions seen with 2.0 and 4.0 mg/kg were associated with antiarrhythmic actions.[2] |

Solubility Information

| | |
|------------|--|
| Solubility | DMSO: 50 mg/mL (153.15 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|--|

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 3.063 mL | 15.3149 mL | 30.6297 mL |
| 5 mM | 0.6126 mL | 3.063 mL | 6.1259 mL |
| 10 mM | 0.3063 mL | 1.5315 mL | 3.063 mL |
| 50 mM | 0.0613 mL | 0.3063 mL | 0.6126 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Pugsley MK, et al. Block of Na^+ and K^+ currents in rat ventricular myocytes by quinacainol and quinidine. *Clin Exp Pharmacol Physiol.* 2005;32(1-2):60-65.
- Howard PG, et al. Quinacainol, a new antiarrhythmic with class I antiarrhythmic actions in the rat. *Eur J Pharmacol.* 1992;219(1):1-8.
- Drobinski G, et al. Haemodynamic effects of intravenous quinacainol with and without autonomic nervous system blockade. *Int J Cardiol.* 1991;30(3):341-347.
- Drobinski G, et al. Hemodynamic effects of quinacainol administered via an intravenous route. Study in patients with normal left ventricular function. *Therapie.* 1990;45(2):119-123.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481